Liver Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Liver Disease stocks.

Liver Disease Stocks Recent News

Date Stock Title
Nov 21 GRI GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
Nov 21 GNFT Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions
Nov 20 GILD Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
Nov 19 NTLA Intellia Therapeutics Announces Promising CRISPR Therapy Results
Nov 19 NTLA ReCode to secure funds for cystic fibrosis gene correction treatments
Nov 19 NTLA Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
Nov 19 NTLA Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Nov 18 ALNY Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis
Nov 18 NTLA Intellia’s gene editing therapy shows early potential in rare heart condition
Nov 18 GILD Gilead’s Livdelzi shows promise in PBC clinical trial
Nov 18 ALNY ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
Nov 18 GALT Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Nov 18 ALNY Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
Nov 18 NTLA CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
Nov 17 ALNY Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
Nov 16 NTLA Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
Nov 15 TARA Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
Nov 15 GILD Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Nov 15 GILD Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Liver Disease

Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the course of the problem lasts long, chronic liver disease ensues.

Browse All Tags